Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Energy stocks remain firm
Wed, 7 Jan 01:30 pm

Indian share markets pared losses but continued to trade in the red in the post-noon trading session. Majority of the sectoral indices are trading in the red with metal and banking stocks being the biggest losers. Energy and auto are among the few stocks trading in the green.

BSE-Sensex is down 39 points and NSE-Nifty is trading 8 points down. Both BSE Mid Cap and BSE Small Cap indices are trading down by 0.1% each. The rupee is trading at 63.40 to the US dollar.

Most of the domestic pharma stocks are trading in the red with Dishman Pharma and Elder Pharma being the biggest losers. As per a leading financial daily, three pharma companies namely Aurobindo Pharma, Lupin and Jubilant Life Sciences have won approval from US Food and Drug Administration (USFDA) to launch generic version of Valsartan tablets used in the treatment of hypertension. As per IMS data, the annulized market size of the drug is around $ 2 bn in the US markets. Lupin has already launched the drug in the US market. Jubilant Life Sciences is planning to launch the drug immediately whereas Aurobindo Pharma has said the product is ready for launch. Aurobindo Pharma stock is trading up 1.7%.

FMCG stocks are trading mixed with Hindustan Unilever and Dabur being the major gainers whereas Marico and Gillette are among the major losers. As per a leading financial daily, Godrej Consumer Products Ltd (GCPL) has further expanded its footprint in the African market by acquiring hair extensions company Frika Hair Pty Ltd based in South Africa. Frika's product range comprises of hair extensions, wigs, synthetic weaves, braids in the premium end of the market. This is likely to provide synergistic benefits to GCPL's haircare portfolio. Rapidol, Kinky, Tura and the Darling Group are the other acquisitions made by the company in Africa. However, Frika's annual revenues of around Rs 400 m may not add significantly to GCPL's overall revenues but it can enable the company to cross-sell products and introduce innovations in the other markets in Africa and UK. The company recently launched the hair colour innovations developed by its African operations in the Indian market. GCPL stock is currently trading up by 0.6%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Energy stocks remain firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.